Source: Kapitales ResearchHighlights

• Recce secured firm commitments to raise AU$4.0 million through an institutional placement and launched a Share Purchase Plan (SPP) targeting up to a further AU$4.0 million, strengthening funding for its next stage of clinical and commercial development.
• Capital will primarily support commercial licensing initiatives with a leading Middle Eastern pharmaceutical company, Phase 3 clinical programs, Investigational New Drug (IND) enabling activities and additional working capital.
• Following completion of the offer, Recce expects pro forma cash liquidity of approximately AU$29.5 million before offer costs, supplemented by anticipated R&D incentives and available debt funding.

Recce Pharmaceuticals Ltd (ASX: RCE) remained unchanged at AU$0.460 after announcing a capital raising designed to reinforce its financial position ahead of several significant clinical and commercial milestones. The company has secured firm commitments to raise AU$4.0 million through an institutional placement while simultaneously providing existing shareholders with the opportunity to participate through a Share Purchase Plan expected to raise up to an additional AU$4.0 million. The funding initiative is intended to support ongoing clinical development, strengthen commercial readiness and enhance financial flexibility as the company advances discussions with an international pharmaceutical partner.Capital Raising Expands Financial CapacityThe institutional placement comprises the issue of 10.0 million new fully paid ordinary shares at an issue price of AU$0.40 per share and was supported by new and existing institutional, sophisticated and professional investors. Eligible shareholders will also be invited to participate in a Share Purchase Plan on identical pricing terms, enabling them to subscribe for up to AU$30,000 worth of additional shares. If fully subscribed, the combined raising could generate up to AU$8.0 million before costs.Funding Prioritises Commercial and Clinical ProgressManagement has outlined a detailed allocation of the expected proceeds. Approximately AU$3.2 million will be directed towards strengthening the balance sheet and supporting commercial licensing initiatives with a leading Middle Eastern pharmaceutical company. A further AU$2.0 million has been allocated to ongoing clinical programs, including completion of the Phase 3 Diabetic Foot Infection registrational trial in Indonesia, commencement of the Australian Phase 3 study designed to support a future US FDA submission, and continuation of the US Department of War Burn Wound Program. Another AU$2.0 million will fund activities required to support Investigational New Drug applications with both the US FDA and Indonesia's BPOM regulator, while approximately AU$0.8 million has been allocated to working capital and offer-related expenses.Liquidity Position Strengthened Ahead of Key MilestonesFollowing completion of the capital raising, Recce expects pro forma cash liquidity of approximately AU$29.5 million before offer costs. Management also anticipates receiving an estimated AU$7.5 million Research and Development Tax Rebate together with approximately AU$10.0 million through its Research and Development Advance facility. In addition, the company retains the ability to access a further AU$10.0 million under its existing Avenue Capital debt facility, providing additional financial flexibility as multiple development programs progress.Offer Structure Rewards Shareholder ParticipationInvestors participating in both the Placement and Share Purchase Plan will receive one free attaching unlisted option for every two new shares issued. Each attaching option carries an exercise price of AU$0.60 and expires on 30 June 2027. Upon exercise of an attaching option, investors will automatically receive two additional unlisted piggyback options exercisable at AU$1.00 until 30 June 2028. Management stated that the option structure is intended to provide shareholders with additional participation opportunities as the company advances its clinical pipeline and commercial objectives.Commercial Momentum Continues to BuildChief Executive Officer James Graham said the successful capital raising follows the execution of a non-binding term sheet with a leading Middle Eastern pharmaceutical company and comes ahead of interim clinical data expected from Indonesia. Management believes the combination of strengthening commercial engagement, advancing late-stage clinical programs and maintaining a well-funded balance sheet positions the company to pursue several important value-creating milestones over the next twelve months as it continues developing its synthetic anti-infective platform.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au